Prometheus Biosciences contends that the current treatments for inflammatory bowel disease are inadequate, taking a “one-size-fits-all approach” that doesn’t account for biologic variation. The ...

The Technology Association of Iowa is pleased to announce the winners of the 2021 Prometheus Awards Presented by LWBJ. The Prometheus Awards were celebrated on Thursday in downtown Des Moines. The ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Meet the winners in our 2021 Fast 50 Awards, highlighting ...

The developers of the popular Prometheus monitoring tool announced a new operating mode for the software today that’s designed to run more efficiently in low-resource environments such as edge ...

Prometheus Biosciences, a Phase 1 biotech developing precision antibody therapies for IBD and related diseases, filed on Friday with the SEC to raise up to $125 million in an initial public offering.